~70% of aggressive solid tumors
contain a TP53 mutation

Addressing an Unmet Need

About Us

PHP Biotech is a US-based biotech company founded by innovative healthcare entrepreneurs and powered by a world-class scientific team specializing in nanobody and translational biotechnology. ​

Our lead candidate, PHP53-nb, is a first-in-class humanized nanobody showing strong anti-tumor efficacy, low toxicity, and a novel mechanism of action. ​

With positive data in triple negative breast cancer models and potential for many other cancer types carrying TP53 mutations there is strong potential as both a stand-alone and add-on therapeutic. The platform can be leveraged for many applications including other oncology targets, immunology and more.

Meet Our Dedicated Team

COO

Research Leader

Board Member